Biovance Capital

All figures cover the European funds tracked here since 1 January 2025, whether closed or still raising, and are compiled from public sources.

Tracked funds

1

Reported volume

€57m

Latest public closing

25 Jun 2025

Reported volume sums the public fund amounts tracked here, not the manager's firm-wide assets under management, so it may differ from totals on the manager's website.

Lisbon-based venture capital firm investing in early-stage biotech companies across Europe.

Focus: Early-stage drug development and biotech, seed and Series A, with a focus on Southern Europe

9 July 2024: first close of its first biotech fund at €51m (company news, EIF).